[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases]

Area of Science:

• Hematology
• Oncology

Background:

• Chronic myeloproliferative diseases (CMPD) encompass a group of disorders characterized by the overproduction of myeloid cells.
• Idiopathic myelofibrosis, polycythemia vera, and essential thrombocythemia are key subtypes of CMPD.

Purpose of the Study:

• To analyze the impact of different therapeutic interventions on survival rates in patients with CMPD.
• To evaluate the effectiveness of cytostatic drugs, erythrocyte mass transfusions, and hemoexfusions (phlebotomy) in CMPD management.

Main Methods:

• Retrospective analysis of 106 case histories of primary CMPD patients.
• Categorization of CMPD subtypes including idiopathic myelofibrosis, polycythemia vera, and essential thrombocythemia.
• Comparison of survival rates based on treatment modalities: cytostatics, erythrocyte transfusions, and hemoexfusions.

Main Results:

• Patients treated with cytostatic drugs had a median overall survival of 156 months, compared to 95.2 months for untreated patients.
• Cytostatic therapy was associated with lower survival rates in CMPD patients with hypocellular bone marrow.
• Erythrocyte mass transfusions correlated with significantly lower survival rates in CMPD patients.
• Hemophoeresis (phlebotomy) was associated with improved median overall survival (193.6 months) compared to patients not receiving it (110.3 months).

Conclusions:

• Therapeutic strategies for CMPD require careful selection, as some interventions may negatively impact survival.
• Hemophoeresis (phlebotomy) appears to be a beneficial treatment modality for improving survival in CMPD patients.
• Further research is warranted to optimize treatment protocols for different CMPD subtypes and patient characteristics.